Communique from the Annual General Meeting in 2cureX AB (publ)

Report this content

Today, on May 28th, 2019, the Annual General Meeting (“AGM”) was held in 2cureX AB (publ). Below follows a summary of the resolutions. The resolutions were passed with the required majority.

Disposition of the company’s profit or loss

The AGM resolved to dispose of the company's results according to the Board's proposal in the annual report. The AGM also resolved that no dividend be paid for the financial year 2018. In addition, the AGM resolved to grant discharge from liability to the members of the Board and the CEO for the financial year 2018.

Determination of the number of Board members, Board deputies and the number of auditors and auditor deputies and determination of fees for the Board and the auditors.

The AGM resolved that the Board of Directors shall consist of five board members and no deputy board member, and that board fees shall be SEK 200,000 to the chairman of the board and with SEK 100,000 each to other board members excluding Timm Jessen and Ole Thastrup. Furthermore, the AGM resolved that one auditor and no deputy auditor shall be appointed and that auditors' fees shall be paid according to approved invoice in accordance with customary charging standards.

Election of Board and auditor

The AGM resolved to re-elect Povl-André Bentz, Camilla Huse Bondesson, Jørgen Drejer, Timm Jessen and Ole Thastrup as board members. Povl-André Bentz was re-elected as Chairman of the Board. Furthermore, the AGM resolved that the company's auditor Öhrlings PricewaterhouseCoopers AB was re-elected until the end of the Annual General Meeting, which will be held next financial year.


The Board, or other by the Board appointed, was authorized to decide on minor corrections required for registration with the Swedish Companies Registration Office.

Certified Adviser

Sedermera Fondkommission
Phone: +46 40 615 14 15

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer
Phone: +45 22 11 53 99

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).


Documents & Links